enGene Holdings Inc. (ENGN)
| Market Cap | 214.12M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 23.20M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,339 |
| Open | 8.30 |
| Previous Close | 8.11 |
| Day's Range | 8.30 - 9.39 |
| 52-Week Range | 6.69 - 47.17 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About ENGN
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada. [Read more]
Financial Performance
Financial StatementsNews
enGene Announces Expanded $50 Million Debt Facility with Hercules Capital
BOSTON and MONTREAL , Dec. 22, 2023 /PRNewswire/ - enGene Holdings Inc. ("enGene," Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead EG-70 program is in a pivotal study for BCG-unre...
enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors
BOSTON and MONTREAL , Dec. 19, 2023 /PRNewswire/ - enGene Holdings Inc. ("enGene," Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsi...
enGene Appoints Ryan Daws as Chief Financial Officer
BOSTON and MONTREAL , Nov. 29, 2023 /PRNewswire/ - enGene Holdings Inc. ("enGene,") (NASDAQ: ENGN) (NASDAQ: ENGNW), a clinical-stage genetic medicines company whose lead program is in a pivotal study ...
Lumira Ventures Portfolio Company enGene (Nasdaq:ENGN) Debuts as Publicly Traded Genetic Medicines Company
CAD$191 million gross proceeds from the transaction to support the advancement of the clinical program and pipeline expansion. Pivotal clinical trial for lead program EG-70 targeting BCG-unresponsive ...
enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company
Business combination transaction completed with Forbion European Acquisition Corp. Clinical stage biotechnology company with EG-70 lead program in pivotal clinical study targeting BCG-unresponsive non...